Danaher Co. (NYSE:DHR) Shares Sold by Western Wealth Management LLC

Western Wealth Management LLC reduced its position in Danaher Co. (NYSE:DHR) by 3.9% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 5,759 shares of the conglomerate’s stock after selling 231 shares during the quarter. Western Wealth Management LLC’s holdings in Danaher were worth $1,332,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of the company. Drive Wealth Management LLC increased its stake in Danaher by 3.1% in the 4th quarter. Drive Wealth Management LLC now owns 1,485 shares of the conglomerate’s stock valued at $344,000 after buying an additional 44 shares during the period. Nations Financial Group Inc. IA ADV increased its stake in Danaher by 0.8% in the 1st quarter. Nations Financial Group Inc. IA ADV now owns 6,064 shares of the conglomerate’s stock valued at $1,779,000 after buying an additional 46 shares during the period. Trust Investment Advisors increased its stake in Danaher by 1.8% in the 4th quarter. Trust Investment Advisors now owns 2,811 shares of the conglomerate’s stock valued at $650,000 after buying an additional 49 shares during the period. New Hampshire Trust increased its stake in Danaher by 0.3% in the 3rd quarter. New Hampshire Trust now owns 14,438 shares of the conglomerate’s stock valued at $3,582,000 after buying an additional 50 shares during the period. Finally, Connolly Sarah T. boosted its position in shares of Danaher by 0.5% during the 3rd quarter. Connolly Sarah T. now owns 9,599 shares of the conglomerate’s stock worth $2,382,000 after purchasing an additional 50 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on DHR shares. Raymond James boosted their target price on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. Barclays boosted their target price on shares of Danaher from $240.00 to $260.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 10th. Royal Bank of Canada boosted their target price on shares of Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Finally, HSBC upgraded shares of Danaher from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $250.00 to $280.00 in a research report on Wednesday. Six research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $268.27.

Insider Activity

In other news, SVP Georgeann Couchara sold 2,622 shares of the company’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the transaction, the senior vice president now owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, SVP Georgeann Couchara sold 2,622 shares of the stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the sale, the senior vice president now owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the sale, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The disclosure for this sale can be found here. Insiders sold a total of 32,957 shares of company stock valued at $8,265,802 in the last 90 days. 11.10% of the stock is currently owned by insiders.

Danaher Price Performance

NYSE:DHR opened at $235.37 on Friday. The firm has a market cap of $174.30 billion, a price-to-earnings ratio of 36.83, a price-to-earnings-growth ratio of 3.59 and a beta of 0.83. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31. The company’s 50-day moving average is $248.94 and its two-hundred day moving average is $230.05. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $259.00.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.18. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The company had revenue of $6.41 billion for the quarter, compared to analyst estimates of $6.10 billion. During the same period in the prior year, the firm earned $2.87 EPS. The firm’s quarterly revenue was down 10.2% on a year-over-year basis. Research analysts expect that Danaher Co. will post 7.62 EPS for the current year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be paid a dividend of $0.27 per share. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.46%. This is an increase from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio is currently 16.90%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.